SAN
JOSE, Calif., Oct. 23,
2023 /PRNewswire/ -- Anixa Biosciences, Inc.
("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company
focused on the treatment and prevention of cancer, today announced
that it has appointed Mark A.
Goldberg, MD, to its Cancer Business Advisory Board
(CBAB).
"We are pleased to welcome Dr. Goldberg as the 9th
independent member of our CBAB," said Dr. Amit Kumar, Chairman and CEO of Anixa
Biosciences. "Mark brings valuable clinical expertise in oncology,
and his extensive biotechnology executive experience will be an
asset to Anixa. In addition, his many years of volunteer service to
the American Cancer Society (ACS), including serving on the
national board of directors and as Board Scientific Officer, give
him a broad perspective on technologies being developed for
cancer." Dr. Kumar continued, "During my time on the board of the
American Cancer Society, I led the effort to form ACS's venture
fund, BrightEdge Ventures, and it was wonderful to have Mark join
with me on the investment committee of the fund. All of these
experiences, will be beneficial for Anixa as we grow."
Dr. Goldberg is a longtime American Cancer Society and ACS
Cancer Action Network volunteer. He has been a member of the ACS
Eastern New England Board since 2017; and a member of the ACS
national board of directors since 2019, serving as Board Scientific
Officer since 2022. Dr. Goldberg currently serves on the boards of
directors of ImmunoGen (NASDAQ: IMGN), GlycoMimetics (NASDAQ:
GLYC), Blueprint Medicines (NASDAQ: BPMC), Avacta Group (LSE:
AVTC), and Walden Biosciences. He previously served as a member of
the ACS New England Division Board from 2010 to 2017; was part of
the executive management team of Synageva Biopharma from 2011 to
2014; and served in various management capacities of increasing
responsibility at Genzyme Corporation from 1996 to 2011, including
as Senior Vice President of Clinical Development. Prior to joining
Genzyme, Dr. Goldberg was a full-time staff physician at Brigham
and Women's Hospital, where he still holds an appointment. He is
also currently a lecturer in medicine at Harvard Medical School. Dr. Goldberg received his
Bachelor of Arts degree from Harvard
College and his medical degree from the Harvard-MIT Program
in Health Sciences and Technology.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the
treatment and prevention of cancer. Anixa's therapeutic portfolio
consists of an ovarian cancer immunotherapy program being developed
in collaboration with Moffitt Cancer Center, which uses a novel
type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple negative breast cancer
(TNBC), the most lethal form of the disease – as well as a vaccine
to prevent ovarian cancer. These vaccine technologies focus on
immunizing against "retired" proteins that have been found to be
expressed in certain forms of cancer. Anixa's unique business model
of partnering with world-renowned research institutions on clinical
development allows the Company to continually examine emerging
technologies in complementary fields for further development and
commercialization. To learn more, visit www.anixa.com or follow
Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contacts:
Stephen Kilmer
Investor Relations
skilmer@anixa.com
646-274-3580
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-appoints-accomplished-medical-oncologist-and-biotechnology-executive-dr-mark-a-goldberg-to-cancer-business-advisory-board-301963745.html
SOURCE Anixa Biosciences, Inc.
